Intravitreal faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration: short and long-term outcomes and assessment of volume dynamics using an artificial intelligence-based tool
Faricimab may offer a valuable alternative for patients with refractory nAMD. The use of four loading injections administered monthly, followed by a treat-and-extend regimen can result in maintenance of visual acuity and improve anatomical parameters and retinal fluid activity, allowing for longer treatment intervals.
Authors
- Yannic Pannatier Schuetz (ORCID: https://orcid.org/0009-0001-3697-9121)
- Aude Ambresin (ORCID: https://orcid.org/0000-0002-6543-3400)
- Mickael Barbosa (ORCID: https://orcid.org/0009-0006-3686-120X)
- Daniela Gallo Castro (ORCID: https://orcid.org/0000-0001-5145-5126)
- Mamadou Pathé Barry
- Anna Chiara Nascimbeni
- Nicolò Bartolomeo (ORCID: https://orcid.org/0000-0001-9522-7176)
Institutions
- SIB Swiss Institute of Bioinformatics (CH)
- Swiss Finance Institute (CH)
Publication Details
- Journal
- International Journal of Retina and Vitreous
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1186/s40942-025-00751-9
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00